Sustained Improvement in Revenue, Profit, Profitability and Financial Stability
First written in FY2019. 14 of 19 entries say "Advanced", first in FY2020-Q3. Latest entry: 2026-09-28.
13 other companies' latest entry also says "Restated".
- FY2026-H1Declining Profit MetricsAnnual report
「Revenue was ¥25,600 million, up 7.5% year on year; operating profit was ¥2,804 million, down 25.1%; ordinary profit was ¥2,789 million, down 26.8%; and interim profit attributable to owners of the parent was ¥1,896 million, down 29.5%.」
While revenue increased in the interim period, operating profit, ordinary profit and interim profit attributable to owners of the parent fell below the year-earlier period. - FY2024ReframedAnnual report
「With the aim of moving to an evaluation that excludes accounting effects and also takes into account the effects of strategic investments, we decided to place greater emphasis on EBITDA than on the previous focus on operating profit. As indicators for measuring enterprise value, we also emphasize growth, as reflected in year-on-year increases in revenue and EBITDA, as well as the EBITDA margin.」
The indicator framework is being reorganized from one centered on operating profit to one emphasizing EBITDA, the EBITDA margin, the equity ratio and the Net Debt/EBITDA multiple. - FY2024-Q1AdvancedAnnual report
「As a result, the operating results of our group for the cumulative first quarter of the consolidated fiscal year were revenue of ¥9,536 million, up 31.4% year on year; EBITDA of ¥3,025 million, compared with ¥2,252 million in the same quarter of the previous year, up 34.3%; operating profit of ¥2,635 million, up 32.7%; ordinary profit of ¥2,577 million, up 30.9%; and profit attributable to owners of the parent of ¥1,817 million, up 29.9%.」
For the first quarter, revenue, EBITDA, operating profit, ordinary profit and profit attributable to owners of the parent for the quarter exceeded the year-earlier period. EBITDA is newly presented alongside the other performance indicators. - FY2023-Q3AdvancedAnnual report
「Going forward, we will pursue proactive openings based on more detailed marketing and opening strategies, while conducting vigorous sales activities targeting medical institutions and others, to achieve long-term, sustainable growth. As a result, the operating results of our group for the cumulative third quarter of the consolidated fiscal year were revenue of ¥22,999 million, up 40.2% year on year; operating profit of ¥6,176 million, up 40.4%; ordinary profit of ¥6,137 million, up 42.0%; and profit attributable to owners of the parent of ¥4,614 million, up 51.0%.」
For the cumulative third quarter, revenue, operating profit, ordinary profit and profit attributable to owners of the parent for the quarter exceeded the year-earlier period. The results reflect improved performance driven by the opening strategy and sales activities. - FY2023-Q2AdvancedAnnual report
「As a result, the operating results of our group for the cumulative second quarter of the consolidated fiscal year were revenue of ¥14,742 million, up 41.9% year on year; operating profit of ¥3,937 million, up 36.5%; ordinary profit of ¥3,940 million, up 40.1%; and profit attributable to owners of the parent of ¥3,063 million, up 54.2%.」
For the cumulative second quarter from October 2022 through March 2023, revenue, operating profit, ordinary profit and profit attributable to owners of the parent for the quarter exceeded the year-earlier period. - FY2023-Q1AdvancedAnnual report
「Going forward, we will actively pursue further openings based on detailed marketing and an opening strategy, while also conducting vigorous sales activities targeting medical institutions and other customers, to achieve long-term, sustainable growth. As a result, for the three-month period of the current consolidated fiscal year, our group reported revenue of ¥7,259 million, up 43.9% year on year; operating profit of ¥1,986 million, up 36.1%; ordinary profit of ¥1,968 million, up 37.4%; and quarterly profit attributable to owners of the parent of ¥1,398 million, up 38.1%.」
For the cumulative first quarter from October to December 2022, revenue, operating profit, ordinary profit and profit attributable to owners of the parent for the quarter exceeded the year-earlier period. The equity ratio was 49.0%. - FY2022AdvancedAnnual report
「Revenue was ¥23,072 million, up 50.5% from the previous consolidated fiscal year; operating profit was ¥6,132 million, up 62.0%; ordinary profit was ¥6,060 million, up 60.4%; and profit attributable to owners of the parent was ¥4,279 million, up 62.9%.」
In the fiscal year ended September 2022, revenue, operating profit, ordinary profit, and profit attributable to owners of the parent increased, while the operating margin rose from 24.7% to 26.6%. - FY2022-Q3AdvancedAnnual report
「Going forward, we will actively pursue further openings based on detailed marketing and an opening strategy, while also conducting vigorous sales activities targeting medical institutions and other customers, to achieve long-term, sustainable growth. As a result, for the nine-month period of the current consolidated fiscal year, our group reported revenue of ¥16,410 million, up 53.0% year on year; operating profit of ¥4,398 million, up 74.9%; ordinary profit of ¥4,323 million, up 69.2%; and quarterly profit attributable to owners of the parent of ¥3,055 million, up 69.1%.」
During the nine-month period, revenue, operating profit, ordinary profit, and quarterly profit attributable to owners of the parent exceeded the year-earlier period, demonstrating improved performance driven by the opening strategy and sales activities. - FY2022-Q2AdvancedAnnual report
「As a result, for the six-month period of the current consolidated fiscal year, our group reported revenue of ¥10,391 million, up 56.0% year on year; operating profit of ¥2,885 million, up 90.7%; ordinary profit of ¥2,811 million, up 78.4%; and quarterly profit attributable to owners of the parent of ¥1,987 million, up 78.5%.」
During the six-month period, revenue, operating profit, ordinary profit, and quarterly profit attributable to owners of the parent exceeded the year-earlier period, continuing the improvement in revenue and profit. - FY2022-Q1AdvancedAnnual report
「Going forward, we will actively pursue further openings based on detailed marketing and an opening strategy, while also conducting vigorous sales activities targeting medical institutions and other customers, to achieve long-term, sustainable growth. As a result, for the three-month period of the current consolidated fiscal year, our group reported revenue of ¥5,044 million, up 59.2% year on year; operating profit of ¥1,459 million, up 102.4%; ordinary profit of ¥1,432 million, up 81.3%; and quarterly profit attributable to owners of the parent of ¥1,012 million, up 81.4%.」
During the three-month period, revenue, operating profit, ordinary profit, and quarterly profit attributable to owners of the parent exceeded the year-earlier period, demonstrating improved performance driven by the opening strategy and sales activities. - FY2021AdvancedAnnual report
「Revenue was ¥15,334 million, up 67.1% from the previous consolidated fiscal year; operating profit was ¥3,784 million, up 101.7%; ordinary profit was ¥3,779 million, up 112.4%; and profit attributable to owners of the parent was ¥2,627 million, up 112.0%.」
In the fiscal year ended September 2021, revenue, operating profit, ordinary profit, and profit attributable to owners of the parent all substantially exceeded the previous year, while the operating margin rose from 20.5% to 24.7%. - FY2021-Q3AdvancedAnnual report
「Going forward, we will actively pursue further openings based on detailed marketing and an opening strategy, while also conducting vigorous sales activities targeting medical institutions and other customers, to achieve long-term, sustainable growth. As a result, for the nine-month period of the current consolidated fiscal year, our group reported revenue of ¥10,724 million, up 66.4% year on year; operating profit of ¥2,514 million, up 91.1%; ordinary profit of ¥2,555 million, up 106.7%; and quarterly profit attributable to owners of the parent of ¥1,807 million, up 108.4%.」
During the nine-month period, revenue, operating profit, ordinary profit, and quarterly profit attributable to owners of the parent increased year on year, demonstrating improvement in revenue and profit driven by the opening strategy and sales activities. - FY2021-Q2AdvancedAnnual report
「As a result, for the six-month period of the current consolidated fiscal year, our group reported revenue of ¥6,660 million, up 63.2% year on year; operating profit of ¥1,513 million, up 49.5%; ordinary profit of ¥1,575 million, up 63.6%; and quarterly profit attributable to owners of the parent of ¥1,113 million, up 64.2%.」
During the six-month period, revenue, operating profit, ordinary profit, and quarterly profit attributable to owners of the parent increased year on year, demonstrating improvement in revenue and profit. - FY2021-Q1AdvancedAnnual report
「As a result, for the three-month period of the current consolidated fiscal year, our group reported revenue of ¥3,168 million, up 61.1% year on year; operating profit of ¥721 million, up 46.8%; ordinary profit of ¥790 million, up 68.9%; and quarterly profit attributable to owners of the parent of ¥558 million, up 69.3%.」
During the three-month period of the fiscal year ending December 2020, revenue, operating profit, ordinary profit, and quarterly profit attributable to owners of the parent increased year on year, demonstrating improvement in revenue and profit. - FY2020AdvancedAnnual report
「As a result of actively opening facilities based on detailed marketing and an opening strategy, together with vigorous sales activities targeting medical institutions and other customers, our group reported revenue of ¥9,174,699 thousand for the current consolidated fiscal year, up 70.9% from the previous consolidated fiscal year; operating profit of ¥1,826,656 thousand, up 100.8%; ordinary profit of ¥1,728,947 thousand, up 99.9%; and profit attributable to owners of the parent of ¥1,204,449 thousand, up 99.9%.」
In the fiscal year ended September 2020, revenue, operating profit, ordinary profit, and profit attributable to owners of the parent all increased substantially, while the operating margin rose from 16.9% to 19.9%. - FY2020-Q3AdvancedAnnual report
「As a result, for the nine-month period of the current consolidated fiscal year, our group reported revenue of ¥6,446,568 thousand, up 73.7% year on year; operating profit of ¥1,291,828 thousand, up 115.0%; ordinary profit of ¥1,211,948 thousand, up 110.6%; and quarterly profit attributable to owners of the parent of ¥850,486 thousand, up 106.6%.」
During the nine-month period, revenue, operating profit, ordinary profit, and quarterly profit attributable to owners of the parent increased year on year, demonstrating improvement in revenue and profit. - FY2019First statedAnnual report
「We aim to expand corporate value in a balanced and sustainable manner, with a focus on improving these metrics. As indicators for measuring corporate value, we also place importance on management growth, as reflected in year-on-year increases in revenue, ordinary profit, and profit attributable to owners of the parent.」
The company lists operating profit, gross margin and operating margin by facility, equity ratio, revenue, ordinary profit, and profit attributable to owners of the parent as its key metrics.